| Protein Name | SMAD Family Member 7 |
| Gene | SMAD7 |
| UniProt ID | O15117 |
| PDB IDs | 1U7V, 1USC, 2L4J |
| Molecular Weight | 46 kDa |
| Subcellular Localization | Cytoplasm, nucleus, plasma membrane |
| Protein Family | SMAD family (inhibitory) |
SMAD Family Member 7 is a SMAD family (inhibitory) member. The protein contains the characteristic domain structure including [domain descriptions]. The molecular weight is approximately 46 kDa, and the protein localizes to Cytoplasm, nucleus, plasma membrane.
SMAD7 is an inhibitory SMAD that blocks TGF-β signaling by binding to TGF-β type I receptor (ALK5) and preventing R-SMAD phosphorylation. SMAD7 recruits E3 ubiquitin ligases to promote receptor degradation. It is a key negative regulator of fibrosis, inflammation, and epithelial-mesenchymal transition. In the nervous system, SMAD7 modulates neuroinflammation, glial scar formation, and neuronal survival. It is upregulated in response to TGF-β to provide feedback inhibition.
SMAD7 variants are associated with colorectal cancer, inflammatory bowel disease (IBD), and fibrosis. In neurodegenerative diseases, SMAD7 may have protective roles by limiting neuroinflammation.
This protein is a potential therapeutic target for neurodegenerative diseases. Research is ongoing to develop small molecule inhibitors and biologics that modulate its activity.
This section provides background information on the gene/protein and its role in the nervous system.
This overview section needs to be expanded with relevant scientific information from peer-reviewed sources.